AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15121740 — intervention group
Group type: COMPARATOR
Intervention: LBNP tolerance
Number of subjects: 40
Study 11176158 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended end-inspiratory pause (EIP)
Number of subjects: 16
Study 11176158 — intervention group
Group type: COMPARATOR
Intervention: 0.2 secs EIP
Number of subjects: 16
Study 9508522 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of erythromycin during fasting state
Number of subjects: 10
Study 9508522 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of erythromycin plus 300 ml of fresh milk (postprandial state)
Number of subjects: 10
Study 9508522 — intervention group
Group type: COMPARATOR
Intervention: 300 ml of fresh milk and normal saline as placebo (postprandial state)
Number of subjects: 10
Study 7564304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociopolitical stressors (recurring and continuous)
Number of subjects: 100
Study 7564304 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal stressors (undesirable life changes)
Number of subjects: 100
Study 7564304 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse sociopolitical conditions
Number of subjects: 100
Study 7564304 — intervention group
Group type: COMPARATOR
Intervention: Personal nature stressors
Number of subjects: 100
Study 2266755 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (exercise at 15% below VT for 12 minutes)
Number of subjects: 11
Study 2266755 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (exercise at 15% above VT for 12 minutes)
Number of subjects: 11
Study 2266755 — intervention group
Group type: COMPARATOR
Intervention: Both groups (collapsed means)
Number of subjects: 11
Study 7395780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous supplements of essential or essential and nonessential amino acids for 2 months
Number of subjects: 0
Study 7395780 — intervention group
Group type: COMPARATOR
Intervention: Nutritional assessment using anthropometric measurements, serum protein content, immune response, and dietary intake diaries
Number of subjects: 0
Study 7395780 — intervention group
Group type: COMPARATOR
Intervention: Dietary intake of nutrients with dietary diaries
Number of subjects: 0
Study 31774510 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) + Radial Extracorporeal Shock Wave Therapy (rESWT)
Number of subjects: 40
Study 31774510 — intervention group
Group type: COMPARATOR
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 40
Study 30910662 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Medical Appointments (SMA)
Number of subjects: 0
Study 30910662 — intervention group
Group type: COMPARATOR
Intervention: Traditional Appointments
Number of subjects: 0
Study 27091469 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice rehabilitation (19 patients)
Number of subjects: 42
Study 27091469 — intervention group
Group type: COMPARATOR
Intervention: Control group (23 patients)
Number of subjects: 42
Study 26008632 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic imaging (radiologic studies)
Number of subjects: 30
Study 24000594 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide 23-valent pneumococcus vaccine (Pneumo 23, Sanofi Pasteur, France)
Number of subjects: 200
Study 24000594 — intervention group
Group type: COMPARATOR
Intervention: Control group (not immunized against pneumococcus infection)
Number of subjects: 200
Study 21715653 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief structured diabetes education programme
Number of subjects: 164
Study 21715653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 164
Study 19232899 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily for 1 to 8 weeks
Number of subjects: 48
Study 16433794 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin challenge test in family 1
Number of subjects: 74
Study 16433794 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin challenge test in family 2
Number of subjects: 74
Study 16433794 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant LTC4S genotype in family 1
Number of subjects: 74
Study 16433794 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant LTC4S genotype in family 2
Number of subjects: 74
Study 16433794 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 gene deletion in both families
Number of subjects: 74
Study 12605339 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation system (CAS) for acetabular implant positioning
Number of subjects: 100
Study 14622610 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% sucrose
Number of subjects: 113
Study 14622610 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose
Number of subjects: 113
Study 14622610 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% glucose
Number of subjects: 113
Study 14622610 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 113
Study 1831908 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 41 656 (10 mg)
Number of subjects: 12
Study 1831908 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (0.25 mg)
Number of subjects: 12
Study 6616310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperproteic diet
Number of subjects: 24
Study 6616310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlipidic-normoproteic diet
Number of subjects: 24
Study 6616310 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 24
Study 6616310 — intervention group
Group type: COMPARATOR
Intervention: Hyperglucidic diet
Number of subjects: 24
Study 29672184 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplement (3g HMB, 14g arginine, 14g glutamine)
Number of subjects: 31
Study 29672184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 29742967 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive fluid therapy
Number of subjects: 3000
Study 29742967 — intervention group
Group type: COMPARATOR
Intervention: Liberal fluid therapy
Number of subjects: 3000
Study 26521887 — intervention group
Group type: COMPARATOR
Intervention: hs-CRP levels > 3 mg/L
Number of subjects: 100
Study 26521887 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 100
Study 25315149 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression + autologous bone graft with bone marrow buffy coat (BBC)
Number of subjects: 45
Study 25315149 — intervention group
Group type: COMPARATOR
Intervention: Core decompression + autologous bone graft
Number of subjects: 45
Study 22545386 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing (NP)
Number of subjects: 60
Study 22545386 — intervention group
Group type: COMPARATOR
Intervention: Nasal septal suture (NSS)
Number of subjects: 60
Study 20202625 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 g/kg)
Number of subjects: 0
Study 20202625 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 0
Study 20202625 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (low dose)
Number of subjects: 0
Study 20202625 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (high dose)
Number of subjects: 0
Study 20202625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16919477 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-arrow shapes
Number of subjects: 0
Study 16919477 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrows
Number of subjects: 0
Study 16088018 — intervention group
Group type: EXPERIMENTAL
Intervention: Public insurance
Number of subjects: 1452
Study 16088018 — intervention group
Group type: EXPERIMENTAL
Intervention: No insurance
Number of subjects: 1452
Study 16088018 — intervention group
Group type: COMPARATOR
Intervention: Private insurance
Number of subjects: 1452
Study 12235578 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 24
Study 12235578 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training
Number of subjects: 24
Study 10638391 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oral dose of YM087
Number of subjects: 6
Study 10638391 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg i.v. dose of YM087
Number of subjects: 6
Study 7718321 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine intravenous magnesium supplements
Number of subjects: 32
Study 7718321 — intervention group
Group type: COMPARATOR
Intervention: Magnesium given on an 'as required' basis
Number of subjects: 32
Study 1688914 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypervolaemic haemodilution with hydroxyethyl starch (HES) combined with exercise (3 times weekly) for 6 weeks
Number of subjects: 75
Study 1688914 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate combined with exercise (3 times weekly) for 6 weeks
Number of subjects: 75
Study 1688914 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone (3 times weekly)
Number of subjects: 75
Study 6586147 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg once weekly)
Number of subjects: 28
Study 6586147 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine (250 mg daily)
Number of subjects: 28
Study 30893022 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology taping of the hemiplegic shoulder
Number of subjects: 10
Study 30149798 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection and prevention program for frailty
Number of subjects: 900
Study 30149798 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 900
Study 27088096 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC continued group (n = 25)
Number of subjects: 49
Study 27088096 — intervention group
Group type: COMPARATOR
Intervention: ABC discontinued group (n = 24)
Number of subjects: 49
Study 24445546 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplemented group (SUP)
Number of subjects: 54
Study 24445546 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 54
Study 23783296 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing docosahexaenoic acid and arachidonic acid (LC-PUFA)
Number of subjects: 235
Study 23783296 — intervention group
Group type: COMPARATOR
Intervention: No LC-PUFAs (control)
Number of subjects: 235
Study 19958072 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified anastomosis with posterior and anterior fixation
Number of subjects: 47
Study 19958072 — intervention group
Group type: COMPARATOR
Intervention: Typical Van Velthoven vesicourethral anastomosis
Number of subjects: 47
Study 18548178 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive physiotherapy rehabilitation on day 1 to 2 after admission until clinical stability
Number of subjects: 76
Study 18548178 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study 15947609 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg daily for 28 days
Number of subjects: 377
Study 15947609 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily for 28 days
Number of subjects: 377
Study 12947315 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol
Number of subjects: 0
Study 12947315 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol-treated islets
Number of subjects: 0
Study 12947315 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 0
Study 9892125 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot pump (intermittent pneumatic pedal compression device)
Number of subjects: 28
Study 9892125 — intervention group
Group type: COMPARATOR
Intervention: Control group (bulky compression dressing, posterior splint, elevation)
Number of subjects: 28
Study 8902991 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg once daily for 10 days
Number of subjects: 442
Study 8902991 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 IU twice daily for 10 days
Number of subjects: 442
Study 1831798 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg DMPA plus 100 mg TE monthly (Group I)
Number of subjects: 20
Study 1831798 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg DMPA plus 250 mg TE monthly (Group II)
Number of subjects: 20
Study 1831798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both steroid regimens (Group I and Group II)
Number of subjects: 20
Study 6753611 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (0.125 mg, 0.25 mg, or 0.50 mg)
Number of subjects: 10
Study 6753611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6753611 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (previously associated dose)
Number of subjects: 10
Study 30932508 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS supported employment
Number of subjects: 541
Study 30932508 — intervention group
Group type: COMPARATOR
Intervention: TW (transitional work) assignments
Number of subjects: 541
Study 28832750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood disorder treatment algorithms
Number of subjects: 259
Study 26400993 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent RV vaccine (RV1) administered to infants
Number of subjects: 107
Study 25396674 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retapamulin ointment 1% (plus oral placebo), twice daily for 5 days
Number of subjects: 404
Study 25396674 — intervention group
Group type: COMPARATOR
Intervention: Oral linezolid (plus placebo ointment) 2 or 3 times daily for 10 days
Number of subjects: 404
Study 22974370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG 1064-nm laser (n=20, 8 J/cm2, 0.25 W, 10 Hz, 10 sec)
Number of subjects: 80
Study 22974370 — intervention group
Group type: EXPERIMENTAL
Intervention: 808-nm diode laser (n=20, 8 J/cm2, 0.25 W, continuous mode, 10 sec)
Number of subjects: 80
Study 22974370 — intervention group
Group type: EXPERIMENTAL
Intervention: 660-nm diode laser (n=20, 8 J/cm2, 0.04 W, continuous mode, 60 sec)
Number of subjects: 80
Study 22974370 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser control (n=20)
Number of subjects: 80
Study 20661659 — intervention group
Group type: EXPERIMENTAL
Intervention: BIB (6 months) followed by diet therapy (7 months)
Number of subjects: 100
Study 20661659 — intervention group
Group type: COMPARATOR
Intervention: BIB followed by another BIB after 1 month
Number of subjects: 100
Study 17462827 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral resuscitation and feeding (ER/EEF) initiated within a median of 10.7h post-burn
Number of subjects: 15
Study 17462827 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feeding (LEF) introduced on average 54h post-burn
Number of subjects: 15
Study 17462827 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 17462827 — intervention group
Group type: EXPERIMENTAL
Intervention: ER/EEF
Number of subjects: 15
Study 15204272 — intervention group
Group type: EXPERIMENTAL
Intervention: Real world assembly instructions
Number of subjects: 114
Study 15204272 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstract assembly instructions
Number of subjects: 114
Study 15204272 — intervention group
Group type: EXPERIMENTAL
Intervention: Task variables identified
Number of subjects: 114
Study 12366892 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched nutrition counseling by family physicians
Number of subjects: 0
Study 12366892 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 9641475 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) 7.2 g per day
Number of subjects: 0
Study 9641475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7865703 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g of piracetam
Number of subjects: 162
Study 7865703 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 g of piracetam
Number of subjects: 162
Study 7865703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 2770269 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine and L-ornithine (2 grams and 1 gram respectively)
Number of subjects: 22
Study 2770269 — intervention group
Group type: COMPARATOR
Intervention: Placebo (600 mg of calcium and 1 gram of Vitamin C)
Number of subjects: 22
Study 143795 — intervention group
Group type: EXPERIMENTAL
Intervention: Live mumps vaccine from the L-3 strain, 1 dose containing 104HAdU50 of mumps virus
Number of subjects: 113967
Study 143795 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 113967
Study 143795 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent vaccination prophylaxis in children's institutions
Number of subjects: 113967
Study 143795 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass prophylaxis by vaccination
Number of subjects: 113967
Study 30747548 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi
Number of subjects: 170
Study 28327932 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant 180 mg oral
Number of subjects: 2595
Study 28327932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2595
Study 28327932 — intervention group
Group type: COMPARATOR
Intervention: Rolapitant and Control (both groups)
Number of subjects: 2595
Study 26123682 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher volume red wine (218 g alcohol/wk)
Number of subjects: 24
Study 26123682 — intervention group
Group type: COMPARATOR
Intervention: Lower volume red wine (73 g alcohol/wk)
Number of subjects: 24
Study 24019545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 517
Study 24019545 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 517
Study 22001171 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand 1 (Caballero Smooth Flavor; 0.89 mg ammonium per gram tobacco)
Number of subjects: 51
Study 22001171 — intervention group
Group type: COMPARATOR
Intervention: Brand 2 (Gauloise Brunes; 3.43 mg ammonium per gram tobacco)
Number of subjects: 51
Study 19500510 — intervention group
Group type: EXPERIMENTAL
Intervention: CRRT without heparin
Number of subjects: 16
Study 19500510 — intervention group
Group type: COMPARATOR
Intervention: CRRT with heparin
Number of subjects: 16
Study 16009365 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 3.0 g/d
Number of subjects: 149
Study 16009365 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 3.75 g/d
Number of subjects: 149
Study 16009365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 12796731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydro-Jet-assisted dissection
Number of subjects: 80
Study 12796731 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection
Number of subjects: 80
Study 11707825 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam and 2 mg hydromorphone p.o. for the contralateral BMBA
Number of subjects: 25
Study 11707825 — intervention group
Group type: COMPARATOR
Intervention: Placebo for the first BMBA and placebo for the contralateral BMBA
Number of subjects: 25
Study 8970608 — intervention group
Group type: EXPERIMENTAL
Intervention: Oduli‐momab (anti‐LFA‐1 mAb)
Number of subjects: 101
Study 8970608 — intervention group
Group type: COMPARATOR
Intervention: rATG
Number of subjects: 101
Study 1591067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (optimal dose 600 mg/m2)
Number of subjects: 40
Study 1591067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (600 mg/m2)
Number of subjects: 40
Study 1591067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (800 mg/m2)
Number of subjects: 40
Study 2412040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (Kn)
Number of subjects: 17
Study 31411096 — intervention group
Group type: EXPERIMENTAL
Intervention: PA delivered VOPD consultation service
Number of subjects: 191
Study 29385055 — intervention group
Group type: EXPERIMENTAL
Intervention: sweet LED preload (low energy density, 50 kcal)
Number of subjects: 32
Study 29385055 — intervention group
Group type: EXPERIMENTAL
Intervention: savoury LED preload (low energy density, 50 kcal)
Number of subjects: 32
Study 29385055 — intervention group
Group type: COMPARATOR
Intervention: HED preloads (high energy density, 250 kcal)
Number of subjects: 32
Study 29385055 — intervention group
Group type: EXPERIMENTAL
Intervention: LED preloads (low energy density, 50 kcal)
Number of subjects: 32
Study 28066102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 500 mg once daily + placebo for 5 days
Number of subjects: 120
Study 28066102 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg twice daily for 5 days
Number of subjects: 120
Study 28066102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 120
Study 28066102 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 120
Study 25399273 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular Closure Devices (VCD)
Number of subjects: 4524
Study 25399273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular VCD
Number of subjects: 4524
Study 25399273 — intervention group
Group type: COMPARATOR
Intervention: Manual Compression
Number of subjects: 4524
Study 23027821 — intervention group
Group type: COMPARATOR
Intervention: α(1) adrenergic agonist (phenylephrine, PE)
Number of subjects: 30
Study 23027821 — intervention group
Group type: COMPARATOR
Intervention: α(2) adrenergic agonist (clonidine, CL)
Number of subjects: 30
Study 23027821 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle sympathetic nerve activity (MSNA)
Number of subjects: 30
Study 20651418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity intervention (LIFE)
Number of subjects: 126
Study 20651418 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise intervention (STRU)
Number of subjects: 126
Study 20651418 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 126
Study 18929012 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing‐based telephone counseling (1 in-person session + 5 telephone sessions)
Number of subjects: 130
Study 18929012 — intervention group
Group type: EXPERIMENTAL
Intervention: Exerciser subgroup
Number of subjects: 130
Study 18929012 — intervention group
Group type: COMPARATOR
Intervention: Control condition (wait-list)
Number of subjects: 130